Company Profile
Capricor Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Capricor Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Capricor Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Capricor Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Capricor Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
CAPR is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Capricor has one very clear focal point in Deramiocel. The BLA review, the fixed PDUFA date, and the cardiac MRI findings all keep the Duchenne program squarely in view, and that is the sort of concrete regulatory path the market tends to watch closely.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy
Source: Capricor Therapeutics
- 02
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Source: Capricor Therapeutics
- 03
- 04
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
Source: Capricor Therapeutics
- 05
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Source: Capricor Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.